Your Gateway for Orphan Drugs, Cell & Gene Therapies in Greece and Cyprus
ORDAID is providing specialized consulting services to pharmaceutical and biotech companies, involved in Rare Diseases and other Niche Therapeutic Areas who are seeking entry in Greece and Cyprus.
We are offering tailored solutions through innovative and effective partnerships with all stakeholders including patient organizations, healthcare professionals and relevant government bodies.
With our specialized focus based on decades of experience, proven track record and expertise, we help pharmaceutical and biotech companies build strategic and productive external stakeholder relations that align with their business goals.
ORDAID’s name is emphasizing our mission that our partners and us are here to aid your company and ensure a successful entry of your Orphan Drug or ATMP into the market in order to serve patients with Rare and other life-threatening Diseases.
Access Strategy
ORDAID management carries years of vast experience in the design, development, and implementation of ethical and responsive pre and post local approval plans for orphan drugs and ATMPs. Our knowledge and personal hands-on experience with orphan drugs and gene therapies will help in designing the appropriate strategy for your product, taking into consideration both the patient’s perspective and the company’s objectives.
Market Research
Research on the incidence and prevalence of Rare Diseases in Greece and Cyprus. Identification of the relevant diagnostic centres and the related treating KOLs. Identification of main specific hospitals for the administration of different Orphan Drugs and the follow up of patient compliance.
Patient Experience Mapping
ORDAID emphasizes on identifying the patient journey from first symptoms to diagnosis, from lack of any treatment to considerations for participation in clinical trials and most importantly the pathway of access to new treatments. We examine issues of access to care and medication, follow up on therapy availability and the impact burden of the specific rare disease on family and their quality of life.
Regulatory
With our highly reliable and experienced local partners, we can provide expert advice in the highly regulated and rather complex environment of the Greek and Cypriot National Health System based on your entry strategy for your company’s orphan drugs and cell/gene therapies.
ORDAID can advise your company in every step of your entry strategy to the Greek Market ranging from HTA file preparation and submission to pricing application and reimbursement discussions.
Marketing and Selling
We aim to provide you with expert advice based on your company’s needs to devise the appropriate Business Plan which will ensure the smooth entry in the market and the successful implementation of your company’s Orphan Drugs and Cell/Gene Therapies.
We can aid your company in devising your entry strategy whether it is creating your own organization or finding the appropriate local partner.
With our hands on experience, we can help your company to create and implement appropriate Awareness Campaigns which are equally important to patients, caregivers and experts.
Staff Selection and Organizational Structure
In the highly specialized and complex world of Orphan Drugs and ATMPs, success is based on People expertise and abilities. We can help you in designing the most effective organizational structure and aid you to identify and select the appropriate people to create the “ideal” team to either initiate or offer a continuation of your business activities based on your company’s vision and objectives.